Abstract
Bisphosphonates are the current standard of care for patients with bone metastases from advanced solid tumors. Zoledronic acid has demonstrated the broadest activity in this setting, and is approved for the prevention of skeletal-related events from bone metastases from a variety of solid tumors in addition to breast cancer and multiple myeloma. Ongoing studies are evaluating the antiresorptive potentials of investigational agents in these settings. A large body of preclinical evidence and recent clinical developments support the hypothesis that zoledronic acid can exert clinically meaningful anticancer activities in some settings, thereby improving disease outcomes and survival. These data are especially strong in breast cancer and multiple myeloma, and are emerging in other cancer settings. This review article will discuss the emerging data suggesting an anticancer role for bisphosphonates in the context of lung cancer and solid tumors other than breast and genitourinary malignancies.
Keywords: Bone metastases, Non-small cell lung cancer, Skeletal-related events, Zoledronic acid, Bone markers, Survival, Skeletal Morbidity, NTX levels, ZOL infusion
Anti-Cancer Agents in Medicinal Chemistry
Title: Bisphosphonates in Lung Cancer: Can They Provide Benefits Beyond Prevention of Skeletal Morbidity?
Volume: 12 Issue: 2
Author(s): Vera Hirsh
Affiliation:
Keywords: Bone metastases, Non-small cell lung cancer, Skeletal-related events, Zoledronic acid, Bone markers, Survival, Skeletal Morbidity, NTX levels, ZOL infusion
Abstract: Bisphosphonates are the current standard of care for patients with bone metastases from advanced solid tumors. Zoledronic acid has demonstrated the broadest activity in this setting, and is approved for the prevention of skeletal-related events from bone metastases from a variety of solid tumors in addition to breast cancer and multiple myeloma. Ongoing studies are evaluating the antiresorptive potentials of investigational agents in these settings. A large body of preclinical evidence and recent clinical developments support the hypothesis that zoledronic acid can exert clinically meaningful anticancer activities in some settings, thereby improving disease outcomes and survival. These data are especially strong in breast cancer and multiple myeloma, and are emerging in other cancer settings. This review article will discuss the emerging data suggesting an anticancer role for bisphosphonates in the context of lung cancer and solid tumors other than breast and genitourinary malignancies.
Export Options
About this article
Cite this article as:
Hirsh Vera, Bisphosphonates in Lung Cancer: Can They Provide Benefits Beyond Prevention of Skeletal Morbidity?, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (2) . https://dx.doi.org/10.2174/187152012799014922
DOI https://dx.doi.org/10.2174/187152012799014922 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radionuclide-Labeled Peptides for Imaging and Treatment of CXCR4- Overexpressing Malignant Tumors
Current Topics in Medicinal Chemistry Synthetic Glycopeptides from the Mucin Family as Potential Tools in Cancer Immunotherapy
Current Cancer Drug Targets The Emerging Role of TRP Channels in Mechanisms of Temperature and Pain Sensation
Current Neuropharmacology Targeting Angiogenesis for Treatment of NSCLC Brain Metastases
Current Cancer Drug Targets Meet Our Editorial Board Member
Current Drug Targets Meet the Guest Editor
Combinatorial Chemistry & High Throughput Screening Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) Thermal [3+2] Cycloaddition Reaction of N-Acyliminophenanthridinium Betaine with Allenoates: Facile Access to Phenanthridine-fused Tetracyclic Heterocycles
Letters in Organic Chemistry Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry Lesson Learned from Nature for the Development of Novel Anti-Cancer Agents: Implication of Isoflavone, Curcumin, and their Synthetic Analogs
Current Pharmaceutical Design Strategies for Stalling Malignancy: Targeting Cancers Addiction to Hsp90
Current Topics in Medicinal Chemistry The Comparison of Rat and Human Intestinal and Hepatic Glucuronidation of Enterolactone Derived from Flaxseed Lignans
The Natural Products Journal From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Garcinia Benzophenones Inhibit the Growth of Human Colon Cancer Cells and Synergize with Sulindac Sulfide and Turmeric
Anti-Cancer Agents in Medicinal Chemistry Novel Fluorescent Benzimidazoles: Synthesis, Characterization, Crystal Structure and Evaluation of Their Anticancer Properties
Letters in Organic Chemistry Metabolic Targets of Cardiac HormonesTherapeutic Anti-Cancer Effects
Current Pharmaceutical Design A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
Current Pharmaceutical Design The Use of PET for Radiotherapy
Current Medical Imaging Immune Modulation by Plasmid DNA-mediated Cytokine Gene Transfer
Current Pharmaceutical Design Pleiotropic Effects of Cardioactive Glycosides
Current Medicinal Chemistry